Loading viewer...
conference
Format: PDF conference
BioPorto presented its NGAL test solution for acute kidney injury at the HC Andersen Capital/Nordea Small Cap Seminar. The presentation covers the company's novel diagnostic platform, addressable market opportunity, regulatory strategy, and development pipeline including the gRAD platform.
BioPorto ProNephro AKITM FDA 510(k) Clearance 2023
investor_presentationinvestor_presentation
9 Pages
conference
12 Pages
TechnipFMC